News

ACADIA Pharmaceuticals accounced that the FDA Psychopharmacologic Drugs Advisory Committee voted that the benefits of Nuplazid (pimavanserin) for the treatment of Parkinson’s disease-related psychosis outweighed the risks of the drug. Nuplazid is a selective serotonin inverse agonist and, if approved, will establish a new and distinctly different pharmacological approach…

Stem cell therapy, which many people living with Parkinson’s disease have long pinned hope on as a potential treatment or even a cure, is finally advancing to clinical trial stage. The recent announcement of a Phase 1/2a clinical trial involving transplantation of stem cells into the first human subjects is…

Living Cell Technologies announced that it has received approval from the Auckland Hospital Research Review Committee to begin a Phase 2b clinical trial evaluating its lead product, NTCELL, as a potential treatment for Parkinson’s disease. Patient recruitment for the trial is now underway, the company said in a press release. NTCELL is an…

The free Hope Flies Health Series Webinar: Research Connecting Parkinson’s Disease and Mitochondrial Disease is scheduled for 1 p.m. Eastern Standard Time on Wednesday, April 6. The event is hosted by the Foundation for Mitochondrial Medicine (FMM) and partners Michael J. Fox Foundation (MJFF), Wilkins Parkinson’s Foundation and…

mPower, a Parkinson’s disease (PD) iPhone app developed by Sage Bionetworks and a team of neurologists at the University of Rochester Medical Center (URMC), marked the first year of its release by being highlighted in Apple Inc.’s “Loop You In” special product launch event on March 21, 2016.

Patients with rosacea may be at an increased risk of new-onset Parkinson’s disease, according to a Danish population study, “Exploring the Association Between Rosacea and Parkinson Disease: A Danish Nationwide Cohort Study,” published in JAMA Neurology. Rosacea is a common chronic inflammatory skin condition characterized…

Rutgers and Stanford University researchers have developed 3-D “scaffolds,” or fibers, that can support healthy and high-functioning human neurons derived from adult stem cells, which can be transplanted to the brain to replace diseased neurons. The technology represents a possible new therapeutic strategy for numerous neurological conditions, including Parkinson’s and Alzheimer’s disease, amyotrophic lateral sclerosis, and multiple…

Multinational research-based biopharmaceutical company AbbVie‘s product DUOPA is a fresh approach to the administration of carbidopa and levodopa for the treatment of motor fluctuations that afflict people with advanced Parkinson’s disease. A researcher, in an exclusive interview with Parkinson’s News Today at the recent  10th World Congress on…

That the formation of alpha-synuclein aggregates, formed by misfolded forms of the protein, is somehow linked to Parkinson’s disease development is a fact few would dispute. Whether preventing the formation, or increasing the clearance of these protein masses, possibly by vaccination, as a viable approach to treatment is, however, a…

Cynapsus Therapeutics, currently conducting a pivotal Phase 3 clinical study of its sublingual formulation of apomorphine to treat “OFF” episodes in Parkinson’s disease (PD), is teaming up with the Michael J. Fox Foundation for Parkinson’s Research (MJFF) for a sub-study that will use wearable technology to gather and analyze…